Valuation: Genelux Corporation

Market Cap 9.19Cr 8.24Cr 7.61Cr 6.9Cr 13Cr 872.58Cr 13Cr 91Cr 36Cr 457.37Cr 34Cr 34Cr 1.45TCr P/E 2026 *
-2.51x
P/E 2027 * -2.61x
Enterprise Value 9.19Cr 8.24Cr 7.61Cr 6.9Cr 13Cr 872.58Cr 13Cr 91Cr 36Cr 457.37Cr 34Cr 34Cr 1.45TCr EV / Sales 2026 *
-
EV / Sales 2027 * 11.7x
Free-Float
86.3%
Yield 2026 *
-
Yield 2027 * -
1 day+7.33%
1 week-18.00%
Current month-18.97%
1 month-17.34%
3 months-30.51%
6 months-19.92%
Current year-52.98%
1 week 1.86
Extreme 1.86
2.35
1 month 1.86
Extreme 1.86
2.66
Current year 1.86
Extreme 1.86
4.99
1 year 1.86
Extreme 1.86
8.54
3 years 1.6
Extreme 1.6
18.01
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 52 02/01/2026
Director TitleAgeSince
Director/Board Member 68 01/09/2002
Chairman 73 01/01/2014
Chairman 67 01/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Sell

Chief Technology Officer

-9,683 0.0214%
31/08/26 Sell

Chief Executive Officer

-34,463 0.0762%
31/08/26 Sell

Chief Technology Officer

-10,257 0.0227%
Change 5-day change 1-year change 3-year change Capi.($)
+7.33%-18.00%-71.92%-84.52% 8.56Cr
-3.10%-4.19%+32.67%+59.47% 6.53TCr
+0.33%+0.33%+10.16%+78.07% 5.46TCr
+0.16%+1.73%+9.89%+102.10% 5.36TCr
-0.75%+1.38%+24.89%+50.91% 4.5TCr
-1.30%-4.80%+16.05%+114.76% 4.22TCr
+1.26%-5.26%+221.12%+900.64% 3.94TCr
-0.74%-4.46%+11.00%+44.65% 3.27TCr
+1.11%+15.18%+60.27%+49.33% 2.65TCr
+3.18%-6.72%+25.35%-8.75% 2.4TCr
Average +0.75%-1.95%+33.95%+130.67% 3.83TCr
Weighted average by Cap. -0.35%-0.59%+42.49%+153.37%

Financials

2026 *2027 *
Net sales - 78.49L 70.44L 65.04L 58.98L 1.1Cr 75Cr 1.12Cr 7.8Cr 3.1Cr 39Cr 2.95Cr 2.88Cr 123.92Cr
Net income -3.7Cr -3.32Cr -3.06Cr -2.78Cr -5.19Cr -351.07Cr -5.26Cr -37Cr -15Cr -184.02Cr -14Cr -14Cr -583.54Cr -4.09Cr -3.67Cr -3.39Cr -3.07Cr -5.75Cr -388.58Cr -5.82Cr -41Cr -16Cr -203.68Cr -15Cr -15Cr -645.89Cr
Net Debt - -
Projected Income Statement - Annual - Genelux Corporation
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
27/26/27 $2.050 +7.33% 14,52,184
26/26/26 $1.910 -4.50% 4,94,701
23/26/23 $2.000 +1.01% 6,48,745
22/26/22 $1.980 -4.35% 9,47,444
21/26/21 $2.070 -17.20% 8,50,725
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Genelux Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.050USD
Average target price
18.83USD
Spread / Average Target
+818.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genelux Corporation
  1. Stock Market
  2. Stocks
  3. GNLX Stock